Compared with the inactivated-vaccine group, the FluMist group had 89.2% fewer cases of influenza A/H1N1, a strain for which the vaccine was well-matched, and 79.2% fewer cases of A/H3N2, which the vaccine did not match well, the report says.
For active immunization of individuals 2 through 49 years of age for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. Though 'definitive,' study lacked placebo groupTreanor, a veteran vaccine researcher and professor of medicine, microbiology, and immunology, commented, "I think one of the things about the study that's remarkable is how carefully done it was and its size. That's what we're gearing up for," she said. One limitation of the FluMist study is that the investigators "did not feel they should include a placebo group," Treanor said. The researchers found no significant difference between the two groups in the overall rate of wheezing episodes. Both FluMist and the injectable vaccines used in the trial, made by Aventis Pasteur, contained the three virus strains recommended by the FDA for the 2004-05 season. Live, attenuated influenza vaccine (called LAIV) is a nasal spray vaccine that may be given to non-pregnant people 2 through 49 years of age. Live attenduated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007 Feb 15;356(7):685-96 [Abstract], Cox NJ, Bridges CB. FluMist Quadrivalent is approved for individuals 2 through 49 years of age. In the international trial conducted in the 2004-05 flu season, there were almost 55% fewer cases of flu in children who received FluMist than in those who received the conventional injectable vaccine, according to a report published in the Feb 15 New England Journal of Medicine (NEJM).
Age Range CVX Code Vaccine Product Billing Code2 CPT AstraZeneca FluMist (LAIV4) 0.2 mL (single-use nasal spray) 0 2 through 49 years 149 90672 GlaxoSmithKline Fluarix (IIV4) 0.5 mL (single-dose syringe) 0 6 months & older3 150 90686 FluLaval (IIV4) 0.5 mL (single-dose syringe) 0 6 months & older3 150 90686 Sanofi Pasteur The investigators also noted that among children who had a history of wheezing, there was a trend toward a higher rate of all-cause hospitalization among 6- to 47-month-olds in the FluMist group, though it was not significant. He said the study strengthens his general impression that the immune response to live attenuated flu vaccines varies with age.
"We're prepared for approval of this expanded indication for next [flu] season.
It takes about 2 weeks for protection to develop after vaccination. Feb 16, 2007 (CIDRAP News) – The live-virus, intranasal influenza vaccine FluMist strongly outperformed conventional killed-virus vaccines in a study involving close to 8,000 children younger than 5 years, a finding that may help pave the way for US approval of the vaccine for that age-group.
The researchers recruited more than 8,300 children, of whom 7,852 completed the study. This vaccine will not treat an active infection that …
Everyone else needs only 1 dose each flu season. The company expects to hear an initial response from the FDA by May 28, Lacey told CIDRAP News. On the basis of their findings, the authors, led by Robert B. Belshe, MD, of St. Louis University, conclude that the vaccine is effective and safe for children from 12 to 59 months old with no history of asthma or wheezing. Everyone else needs only 1 dose each flu season. "It's a pretty convincing result," commented vaccine expert John Treanor, MD, of the University of Rochester (New York), who was not involved in the research. CIDRAP | Office of the Vice President for Research | Contact U of M | Privacy Policy, FDA approves refrigerated form of FluMist, US sees highest COVID-19 daily death toll since May, Vaccine-hesitant parents especially leery of flu shots, study finds, At midseason, flu vaccine yields 45% protection in US, 58% in Canada, Flu activity high; at least 2,100 deaths this season, Office of the Vice President for Research. FluMist® Quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine [see DESCRIPTION]. Participants and medical workers were blinded to the treatment assignments. FLUMIST QUADRIVALENT is a vaccine indicated for active immunization of persons 2-49 years of age for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. Last month the Food and Drug Administration (FDA) approved a new formulation that requires refrigeration but not freezing. Study included 16 countriesThe study involved 249 physcians' offices and clinics in 16 countries, with about half of the sites in the United States. In young and middle-aged adults it appears that the two types are roughly equivalent, though the live vaccine may be slightly better, while inactivated vaccine seems to work better in elderly people, he added.